Ligand Pharmaceuticals Inc

In 2Q17, United Therapeutics (UTHR) reported revenue of ~$445 million, representing year-over-year growth of around 8%.

Ligand Pharmaceuticals has developed a product portfolio that spans more than 700 patents offering varying degrees of protection to the assets.

Ligand Pharmaceuticals’s (LGND) product portfolio has expanded from nine programs in 2008 to 140+ programs in 2016.

Today, US pharmaceutical firm Ligand Pharmaceuticals (LGND) fell 25% from yesterday’s closing price to a low of $98.86 for the day.

Jakavi reported sales of $228.0 million in 4Q17, which is a year-over-year rise of 33.0% on a constant currency basis.

On September 20, 2017, Alnylam Pharmaceuticals (ALNY) announced positive top-line results from phase three trial APOLLO.

Of the nine analysts covering Acadia Pharmaceuticals in September 2017, two rated the stock a “strong buy,” six rated it a “buy,” and one rated it a “hold.”

Eli Lilly’s (LLY) Captisol-enabled drug Prexasertib is currently being evaluated in multiple oncology indications such as head and neck cancer, small-cell lung cancer (or SCLC), and advanced metastatic cancer.

With Sparsentan, Retrophin and Ligand Pharmaceuticals could become major nephrology players similar to peers such as Amgen (AMGN), AstraZeneca (AZN), and Bristol-Myers Squibb (BMY).

Ligand Pharmaceuticals (LGND) receives royalties from Novartis on Promacta’s sales according to a tiered annual payment structure.

Promacta was discovered by Ligand Pharmaceuticals (LGND) and GlaxoSmithKline (GSK) as a part of their thrombopoietin (or TPO) receptor agonist research collaboration.

Ligand Pharmaceuticals (LGND) has entered multiple fully funded partnerships by licensing its technology platforms such as OmniAb, Captisol, LTP Technology, and SUREtechnology Platform.

Ligand Pharmaceuticals (LGND) expects its licensees to invest ~$2.0 billion for advancing more than 155 partnered research and development programs in 2017.

Ligand Pharmaceuticals (LGND) has developed a business model called Shots-on-Goal, which is based on fully funded partnerships.

In 2Q17, Ligand Pharmaceuticals (LGND) reported revenues of ~$28.0 million, representing year-over-year growth of ~43.4%. LGND received ~$14.2 million in royalties, a year-over-year rise of 45.7%.

Merck (MRK) launched Keytruda in 4Q14 and reported global sales of $584 million for 1Q17. As a result, the company reported ~134% growth in revenues compared to $249 million in 1Q16.

Ligand Pharmaceuticals (LGND) is a high-growth company with a comparatively low-risk business model. It earns most of its revenue from royalty and license fees.

Three analysts recommended a “buy” for Agios (AGIO), eight analysts recommended a “hold,” and no analysts recommended a “sell” for the stock. Agios has a weight of 2.2% in XBI’s portfolio.

In this series, we’ll be looking at Ionis Pharmaceuticals’ (IONS) products and other factors that drive its revenues. This will give us a better understanding of what drives Ionis’s revenues.

Incyte is a biopharmaceutical company that’s focused on the discovery, development, and commercialization of oncology drugs.